研究单位：[1]Department of Gynecology and Obstetrics,Tongji Hospital,Huazhong University of Science and Technology[2]Qilu Hospital,Shandong University Jinan,Shandong,China,250012[3]Women's Hospital,School of Medicine,Zhejiang University Hangzhou,Zhejiang,China,310006
研究目的：
We will conduct a trial to determine whether paclitaxel/cisplatin (TP) as an adjuvant chemotherapy after radical surgery improve disease-free survival (DFS) and overall survival (OS), as well as the quality of life (QoL) among early-stage (FIGO stage IB-IIA) cervical cancer patients with risk factors.
